Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Porcine PCV2 Vaccine is a nucleic acid-based (DNA/RNA) vaccine candidate being developed by SET Technology for the prevention of Porcine Circovirus Type 2 (PCV2) infection in swine. PCV2 is a significant pathogen in the global pork industry, associated with Porcine Circovirus Disease (PCVD), which includes symptoms such as wasting, respiratory distress, and skin lesions. The vaccine aims to leverage SET Technology's platform to provide effective immunization against the virus. As of early 2025, the program is in the preclinical optimization phase.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Porcine PCV2 Vaccine.